Lexagene does not say why trading volume is up, but...
AT THE request of IIROC, Lexagene Holdings Inc. confirms that the company’s management is unaware of any material change in the company’s operations that would account for the recent increase in market activity.
The company is still on track and excited for completing the LX6 Alpha prototype by the end of November.
About LexaGene Holdings
LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is ope n-access. The open-access feature will empower end users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press and go. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection. The instrument will be able to process six samples at a time, in an on-demand fashion, returning results in about one hour. The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.
We seek Safe Harbor.
Manohar Furtado, Eric Olsen, Daryl Michael Rebeck, John F Regan, Tom Slezak
(LXG) Shares: 51,676,833